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Abstract 
Objective: The surveillance of acute flaccid paralysis (AFP) is a key strategy for monitoring the progress of 
poliomyelitis eradication and is a sensitive measure for detecting potential cases of poliomyelitis and 
poliovirus infection. This study was conducted to describe the characteristics of patients reported with AFP, 
and to evaluate the performance of the surveillance system in Kurdistan province, western Iran, using 
indicators recommended by the World Health Organization (WHO). 
Methods: This observational study was conducted from January 2000 to December 2010 at the Kurdistan 
Center for Disease Control and the Department of Pediatrics. All children who fulfilled the WHO definition for 
AFP were included in our study. The stool samples of all the children were sent for poliovirus isolation. All the 
patients were evaluated for 60 days after the onset of symptoms to identify the signs of residual weakness. 
Findings: One-hundred thirty nine children aged <15 years were reported to the Center for Diseases Control 
with AFP. In 138 (99%) stool samples no poliovirus was isolated. None of the patients was diagnosed as 
having acute poliomyelitis or polio-compatible paralysis. Guillain-Barré syndrome was the most frequent final 
diagnosis (79 cases) followed by Transverse Myelitis (7 cases) and Encephalitis (6 cases). By detecting 1.3 to 
3.6 (mean 3.2) AFP cases per 100 000 population in Kurdistan during the study period, we achieved the WHO 
target for AFP surveillance. All performance indicators but one consistently met the WHO requirements and 
therefore demonstrated the effectiveness of the AFP surveillance program in Kurdistan. 
Conclusion: The effective surveillance system in Kurdistan and its evaluation may serve as a model for the 
surveillance of other infectious diseases. 
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Introduction 
Poliomyelitis is a highly infectious disease caused 
by poliovirus. It can affect any age, but primarily 
involves children aged less than 5 years and 
causes paralysis in one out of every 200 to 1000 
infected individuals[1,2]. Eradication of polio-
myelitis is attained through widespread 
immunization, and vigilant surveillance for acute 
flaccid paralysis (AFP), reinforced with laboratory 
implementation[3,4]. Surveillance should be 
performed not only for paralytic poliomyelitis, but 
also for other conditions including Guillain-Barré 
syndrome (GBS), among children aged less than 
15 years. Therefore, the surveillance system was 
organized to identify the clinically suspected cases 
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of poliomyelitis, and then to track them using 
laboratory investigations to either rule in or rule 
out the diagnosis of poliomyelitis caused by the 
wild poliovirus.   
     AFP surveillance is a key strategy for 
monitoring the progress of polio eradication and 
is a sensitive measure for detecting the potential 
cases of poliomyelitis and poliovirus infection. The 
World Health Organization (WHO) has devised a 
set of performance indicators to ensure that AFP 
surveillance is properly maintained[1,5,6]. 
Evaluation of AFP surveillance should be based on 
these performance indicators.  
     The Polio Eradication Program was started in 
Iran in 1991. In 1998, an active surveillance 
program for AFP was established by the Iranian 
Government based on new indictors 
recommended by WHO guidelines[7]. Kurdistan is 
one of the largest provinces in west Iran, with a 
population of about 1.5 million[8, 9]. The last case of 
poliomyelitis was reported in 1995. Kurdistan has 
the largest common border with Iraq and may be 
the portal tray of poliomyelitis from this country. 
On the other hand, Afghanistan and Pakistan 
represent a common epidemiological reservoir of 
poliovirus. The indigenous transmission of wild 
poliovirus in these countries has never been 
eradicated. The long border of Iran with these two 
countries requires continuous and vigilant 
surveillance system to timely detect poliomyelitis 
cases. Poliomyelitis has been a statutory 
reportable infectious disease in Kurdistan.  
     We aimed to describe the characteristics of 
patients reported with AFP, and to evaluate the 
performance of the AFP surveillance system using 
indicators  recommended by the WHO. Our study 
summarizes the findings of the AFP surveillance 
conducted in Kurdistan during 2000-2010. 
Subjects and Methods  
This observational study was conducted at the 
Kurdistan Center for Diseases Control and the 
Department of Pediatrics, Kurdistan University of 
Medical Sciences. The study was done during 
January 2000 to December 2010. 
     The four steps of AFP surveillance 
recommended by WHO were followed as[9,10]:  
1. Finding and reporting children with AFP 
2. Transporting stool samples for analysis  
3. Isolating and identifying poliovirus in the 
laboratory  
4. Mapping the virus to determine the origin of the 
virus strain.  
     Initially, a questionnaire was designed, based 
on data recommended by WHO guidelines[5]. Case 
definition (of what should be reported) was 
embedded and defined clearly. The WHO has 
defined AFP as “any child under 15 years of age 
with acute onset of focal weakness or paralysis 
(including GBS)” or any person with paralytic 
illness at any age when polio suspected, 
characterized by flaccid (reduced tone), without 
other obvious causes (e.g. trauma)[5,9]. Transient 
weaknesses such as postictal weakness should not 
be reported as AFP[11]. Data regarding the 
demographic characteristics of the patients, dates 
of evaluation, diagnosis, follow-up, and laboratory 
findings were included in the questionnaire. All 
documents including copies of the patients' charts, 
laboratory findings, imaging and electrodiagnostic 
evaluations (electromyography [EMG] and nerve 
conduction velocity studies [NCS]) even if 
performed in other hospitals were collected in an 
exclusive file.  
     Data were sought out by visiting or contacting a 
feed-forward site. Medical records and registers of 
the site were reviewed to identify the cases. 
     The staffs in all health facilities – from district 
health centers to large hospitals were educated to 
promptly report every case of acute flaccid 
paralysis (AFP) in any child less than 15 years of 
age. Our public health staff made regular weekly 
visits to hospitals and all private medical clinics to 
search for AFP cases which may have been 
overlooked or misdiagnosed. A specially designed 
form had to be signed by attending physicians in 
the health care centers for any suspicious case or 
"zero reporting" of AFP. All children with AFP 
were reported and tested for wild poliovirus 
within 48 hours of onset, even if the physicians 
were confident on clinical grounds that the child 
did not have polio. Close contacts of the patients 
were traced to ensure that they had been fully 
immunized. 
     According to the WHO guidelines, which 
require that ‘adequate’ stool samples be collected 
within 14 days of the onset of paralysis, two 
specimens – taken 24-48 hours apart – were 
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gathered. Stool specimens were sealed in 
containers and stored immediately inside a 
refrigerator or packed between frozen ice packs at 
4–8°C in a cold box, and shipped to the national 
laboratory in Tehran within 72 hours of collection. 
The National Polio Laboratory (NLP) is located at 
the School of Public Health affiliated to Tehran 
University of Medical Sciences and has been 
integrated into the network of polio laboratories 
run by the World Health Organization since 1996. 
It is also a WHO-accredited laboratory to perform 
intra-typic differentiation of polioviruses[12]. More 
recently, the Iran National Polio intratypic 
differentiation (ITD) Laboratory has been 
accredited again by WHO from May 2010 to April 
2011 based on the overall review for 12 months. 
The Laboratory had passed the proficiency test. 
     From January 2000 to December 2010, all 
children who fulfilled the WHO definition for AFP 
were included in our study. All the patients were 
evaluated for 60 days after the onset of symptoms 
to identify the signs of residual weakness. The AFP 
committee of the Kurdistan University of Medical 
Sciences formed an Expert Panel consisting of 
three consultants including a pediatric infectious 
diseases sub-specialist, a neurologist, and an 
infectious diseases specialist to classify the AFP 
cases according to the WHO recommendations 
[5,6,9]. The WHO protocol for case classification was 
followed to determine which patients should 
undergo review by the expert panel (Fig. 1). This 
group included patients whose stool specimens 
were insufficient for laboratory diagnosis, who 
still suffered from residual weakness, or who had 
not been followed up. A detailed case report was 
given to each panel member who independently 
evaluated each case. The panel members’ views 
and comments were documented and a consensus 
was reached for the final classification of each 
patient. The diagnosis was made following a 
complete review of the clinical and epidemio-
logical data, EMG and NCS studies follow up 
outcome and laboratory results of stool cultures 
for polio and non-polio enteroviruses provided by 
NPL. The AFP committee designed a special sheet 
and feed forward forms. These forms were filled 
up and signed by members of the provincial 
committee every 3 months and faxed to the 
 
Fig. 1: Virological flowchart and case classifications.[6, 9] (The permission citing this 
figure was obtained from the WHO, with the permission ID: 102317) 
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National Expert Committee (NEC) in Tehran. If the 
cause of a case of AFP could not be determined at 
the provincial level, the case was referred to the 
NEC, which was responsible for the final diagnosis. 
This committee consists of eight experts (a 
pediatrician, virologist, infectious diseases 
specialist, neurologist, and an epidemiologist). 
NCC convenes several times per year, reviews 
reports, interacts with the provincial committee 
and the NLP, and prepares an annual report of the 
situation for the WHO Eastern Mediterranean 
Regional Office (EMRO)[13]. After final approval of 
the data by NCC, feedback was provided to the 
provincial committee . 
     The detected cases were divided into four 
different age groups. Then in order to estimate the 
annual incidence rate of AFP in population aged 
less than 15, we used the Poisson regression. The 
data were analyzed using R software, version 2.15 
to generate statistics based on the WHO 
performance indicators. P-values below 0.05 were 
considered statistically significant. 
Findings 
One-hundred thirty nine children with acute 
flaccid paralysis aged from 2 months to 14 years 
were reported to the Center for Diseases Control 
during 2000-2010 periods. Table 1 shows the 
incidence of AFP by age and sex. According to the 
Poisson regression analysis, the incidence of 
diseases manifesting as AFP such as GBS were 
highest in early years of age, 66% of patients were 
less than 6 years old [Relative Risk (RR) =5.93, 
95% Confidence interval (CI): 3.2, 10.7, P<0.001]. 
Males comprised a slightly higher percentage 
(55%) of cases than females. However this 
difference was not statistically significant 
[RR=0.93, 95% CI: 0.77, 1.12, (P=0.5)]. Sixty 
percent of children were from urban areas. 
     In 139 (100%) of the cases stool samples were 
sent for poliovirus isolation. Stool examination 
was adequate in all cases and was sufficient to 
exclude poliomyelitis. In 138 (99%) stool samples 
no poliovirus was isolated (Table 2). In one stool 
sample, vaccine poliovirus was isolated. This child 
was vaccinated one week after the occurrence of 
paralysis and therefore paralysis was not related 
to polio vaccination. The child had an uneventful 
recovery. 
     During the study period, all cases were 
classified according to the virological flowchart 
(Fig. 1). The Expert Panel reviewed 139 cases. 
Diagnoses of the 139 confirmed cases are shown 
in Table 3. The major clinical causes of AFP were 
GBS (56.8%), central nervous system (CNS) 
infection (4.3%), CNS tumors (5.1%), transverse 
myelitis (5%), myasthenia gravis (2 cases), 
hypokalemic paralysis (2 cases), and botulism 
(one case). The presentations of 3 cases of GBS 
were as Miller Fischer syndrome. The diagnosis of 
GBS was based on the classic clinical feature of 
symmetric ascending paralysis. In the 37% of the 
cases EMG and NCS were performed but 
cerebrospinal fluid analysis data were available 
for only 13% of the cases. In some cases with 
dominant CNS manifestation, MRI or CT scan of 
the brain or spinal cord was performed to rule out 
mass occupying lesions. Most children had an 
uneventful recovery, but residual weakness 
persisted in 28 (20%) patients. Four children with 
the final diagnosis of GBS (1 case), encephalitis (1 
case), congenital myopathy (1 case) and metabolic 
encephalopathy (1 case) expired. None of the 
children was classified as polio-compatible
Table 1: Mean annual incidence rate of AFP per 100,000 under 15 year old children                                                              
by age and gender using Poisson regression analysis 
P. value 95% CI Relative risk AFP Rate Population Number (%)  Variable 
<0.001 (3.27-10.78) 5.93 6.8 44991 34 (24.5) 0–1 
Age 
groups 
(years) 
<0.001 (3.15-9.52) 5.48 6 87330 58 (41.7) 2–5 
0.01 (1.21-4.03) 2.20 2.4 113963 31 (22.3) 6–10 
- - 1 1.1 131768 16 (11.5) 11–14 
- - 1 3.1 183994 63 (45.3) Female 
Gender 
0.4 (0.82-1.6) 1.15 3.5 194058 76 (54.6) Male 
- - - 3.34 378052 139  Sum 
   AFP: acute flaccid paralysis; CI: Confidence interval  
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or having acute polio-
myelitis. Eleven cases that 
were primarily reported as 
AFP by primary care 
physicians were discarded 
by the AFP provincial 
committee because their 
clinical pictures were not 
compatible with the 
definition of acute flaccid 
paralysis[14]. The stool 
cultures for all of them were 
negative and all had an 
uneventful recovery. The 
results of these cases were 
not counted in the final 
report to avoid over 
diagnosis and over-counting 
the AFP cases. All of these 
cases with their classification 
were reported to NEC and 
feedback was provided by 
NEC. 
     The overall incidence of 
AFP was calculated as 1.3 to 
3.6 (mean 3.2) per 100 000 
population in Kurdistan 
during the study period 
(Table 2). The incidence was 
lowest in the early years of 
the study and received 
highest (6.1) in 2006. The 
mean incidence of GBS was 
calculated as 1.7. 
     During the study, a high 
coverage rate for poliovirus 
vaccination was maintained. 
Based on several studies 
with cluster sampling, the 
coverage rate for 3 doses of 
oral poliovirus vaccine 
remained well high at about 
100% (Table 2).  
     The peak incidences of 
AFP occurred during May 
(14 patients) and June (17 
patients), which coincides 
with the higher enterovirus 
activity associated with 
summer months (Fig. 2). 
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Fig. 2: No. of acute flaccid paralysis (AFP) cases reported by month from 2000 to 2010 
Discussion 
GBS was the most common cause of AFP in our 
study, which is consistent with the findings of 
other studies[15-19]. This syndrome occurs 
throughout the world with an annual incidence of 
0.4-4 (Mean 1.3) cases per 100 000 population[20-
27]. Our surveillance data suggest that about seven 
cases of GBS per year will be diagnosed with 
paralytic presentations in Kurdistan. Considering 
the population in Kurdistan, this figure for 
individuals under 15 years of age gives a mean 
incidence of 1.7 per 100000.   
     The diversity of end diagnosis of AFP patients 
was similar to other reports with some differences 
(Table 3)[15,17-19,28-32]. Transverse myelitis and 
encephalitis were the second and third diagnosis 
in number. Myositis and toxic synovitis of the hip 
were among the less frequent diagnoses in other 
series[17,19,33,34]. Notably, in a few reports trauma 
or posttraumatic lesions had been reported as 
AFP[17]. In some cases, the underlying mechanism 
initially had been obscure so necessitated 
investigation of the cases to rule out poliomyelitis. 
However when the trauma is clear mechanism of 
the paralysis, it should not be reported as AFP in 
the final report[5,9]. 
     The diagnoses of AFP is very diverse because 
many diseases can mimic symptoms and signs of 
poliomyelitis[9]. The AFP surveillance system is a 
syndromic approach to diagnosis of poliomyelitis. 
Accordingly, the diagnosis reports should be 
mostly based on symptoms and signs of a specific 
involved organ system. Etiological diagnosis 
should be reserved for the specific diagnosis of 
poliomyelitis. Using both organ specific and 
etiological agents for reporting diagnoses other 
than poliomyelitis may be misleading in 
developing countries. In many developing 
countries, diagnosis by etiological agent has only 
been possible in remote specialized reference 
laboratories for poliovirus using specific culture 
media. The AFP surveillance system should be 
based on a unique guideline for reporting specific 
diagnoses to be able to compare results of many 
locations and countries. This improves the legal 
framework for coordinating efforts to confine 
poliomyelitis.   
     The WHO has defined the target of detecting at 
least one AFP case per 100 000 in children 
under15 years of age per year as a measure to 
evaluate the effectiveness of AFP surveillance[4]. 
This ratio was increased to two cases per 100 000 
because Iran is near polio-endemic countries such 
as Afghanistan, Pakistan and Iraq[35]. By detecting 
1.3 to 3.6 (mean 3.2) cases per 100 000 
population in Kurdistan comparing 3.1 to 3.3 rate 
for Iran and 4.4 to 5.6 for Eastern Mediterranean 
Region of WHO during the study period, we 
achieved the WHO target for AFP surveillance.  
     The number of reported cases of AFP was 
relatively higher during the summer months 
because of higher enterovirus activity. However, 
the AFP incidence is mostly a reflection of GBS 
incidence. Data about prevalence of GBS in special 
seasons are inconsistent[36,37]. Most studies 
indicate that this syndrome is sporadic without 
significant variation over time[23,24]. Adequate 
virological examination was performed for more 
than 90% of patients (Table 2). Virus isolation
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from feces or throat swabs was successful for only 
a minimum of 5% of the patients. WHO target for 
non-polio enterovirus isolation rate is 10%[5]. This 
indicator remained regularly below the acceptable 
rate in recent years in our country (Table 2). 
According to Polio Laboratory Network update "A 
major change in 2000 is the substitution of 
poliovirus-specific L20B cells for NPEV-sensitive 
Hep2 cells in National Reference Polio 
Laboratories. Because isolation of NPEV now 
depends solely on RD cells, annual rates for most 
laboratories are expected to be lower than in 
previous years." How much lower is still 
unclear[38]. The NPEV rate is no longer a strict 
criterion for accreditation of reference 
laboratories because the isolation rate is affected 
by various factors such as the season of the year, 
altitude, or population hygiene levels[39]. However, 
the rate may be a useful indicator of laboratory 
performance. Consequently, there is a need to 
improve the virological culture technique of 
patients with AFP in our country. Other 
performance indicators have met WHO criteria 
with regard to AFP rate, timeliness of reporting, 
and adequate epidemiological investigations 
(Table 2). These indicators demonstrated the 
effectiveness of the AFP surveillance program in 
Kurdistan. 
     Our report shows that improvements are 
needed, particularly with regard to laboratory 
investigation of AFP cases. "Satisfactory AFP 
surveillance programs rely on three factors: 
detection, investigation, and timely reporting of 
cases[1]." AFP surveillance results in our region 
indicate that vigilance in case detection and 
reporting meet the WHO standards. Meanwhile, 
the increase in notifications suggests an increased 
rate of enthusiasm in reporting. This seems to be 
influenced by an increase in the physicians’ 
awareness. The completeness and accuracy of 
reporting was further improved by reviewing 
hospital discharge records as secondary data 
sources.  
     Our study was disadvantageous for the some 
disorganization of data collected during early 
years of the study. Another limitation of our study 
is that the data collection using questionnaires 
was done by health care workers and therefore, 
some answers could be subject to error and may 
be less reliable. 
Conclusion 
The surveillance system for AFP was effective in 
Kurdistan province and compares well in most 
aspects with other systems in the Eastern 
Mediterranean region. The surveillance system 
and its evaluation may serve as a model for 
surveillance of other infectious diseases. 
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